CN102526613B - Medicament for treating allergic cutaneous vasculitis - Google Patents
Medicament for treating allergic cutaneous vasculitis Download PDFInfo
- Publication number
- CN102526613B CN102526613B CN 201110462360 CN201110462360A CN102526613B CN 102526613 B CN102526613 B CN 102526613B CN 201110462360 CN201110462360 CN 201110462360 CN 201110462360 A CN201110462360 A CN 201110462360A CN 102526613 B CN102526613 B CN 102526613B
- Authority
- CN
- China
- Prior art keywords
- gram
- cutaneous vasculitis
- allergic cutaneous
- medicament
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicament for treating allergic cutaneous vasculitis, and aims to select herbal medicines having the effects of clearing away heat and toxic materials, inducing diuresis, reducing edema, supplementing qi and nourishing blood according to the knowledge of the pathogenesis of allergic cutaneous vasculitis in the national traditional medicine and the treatment principle ofallergic cutaneous vasculitis. The medicament is prepared from the following components by weight: 12g of honeysuckle flower, 16g of roasted astragalus, 12g of virgate wormwood herb, 18g of indian buead, 15g of beautiful sweetgum fruit, 10g of pseudo-ginseng root, 15g of large-head atractylodes rhizome, 18g of Chinese lobelia herb, 20g of turmeric, 20g of prepared rehmannia root, 20g of dangshen,15g of white hyacinth bean, 15g of Chinese atractylodes, 20g of oriental waterplantain rhizome, 15g of hiraute shiny bugleweed herb and 10g of Chinese yam. The components are uniformly mixed and smashed into fine powder of 150 meshes, and the fine powder is taken with warm water.
Description
Technical field the invention belongs to technical field of Chinese medicines, relates to a kind of medicine for the treatment of allergic cutaneous vasculitis, specifically the Chinese patent medicine of preparation take Chinese herbal medicine as raw material.
" pyretic toxicity multiple abscess " in the background technology allergic cutaneous vasculitis ownership traditional Chinese medical science ancient books, think that primary disease is that body hinders in the QI and blood passages through which vital energy circulates interior damp and hot accumulateing, cause stagnation of QI-blood, for a long time and QI and blood is all empty, produce obvious pleomorphism skin lesion, purpura property pimple or maculopapule are its characteristic infringement, and severe patient can involve mucosa and internal organs multisystem simultaneously.Western medical treatment often adopts corticosteroid hormone, sulfone class medicine, nonsteroidal anti-inflammatory drug etc., and these Drug therapys are should disease unsatisfactory and mostly larger to the human body side effect.Treatment has superiority the traditional Chinese medical science to this disease, utilizes heat-clearing and toxic substances removing, inducing diuresis and reducing edema, the benefiting QI and nourishing blood rule for the treatment of that preferably effect is arranged.Therefore invent a kind of medicine for the treatment of allergic cutaneous vasculitis.
Summary of the invention the purpose of this invention is to provide a kind of medicine take heat-clearing and toxic substances removing, inducing diuresis and reducing edema, benefiting QI and nourishing blood as the treatment allergic cutaneous vasculitis of the rule for the treatment of, to overcome the deficiencies in the prior art.
The objective of the invention is according to pathogenetic understanding and the Therapeutic Principle thereof of motherland's medical tradition medical science to allergic cutaneous vasculitis, with reference to modern pharmacological research, therefrom filter out the natural Chinese medicinal herb of heat-clearing and toxic substances removing, inducing diuresis and reducing edema, benefiting QI and nourishing blood, by the theory of Chinese medical science prescription, it is played a role.
Medicine of the present invention is made by following component:
The Flos Lonicerae 12 gram Radix Astragali Preparatas 16 gram Herba Artemisiae Scopariaes 12 gram Poria 18 gram Fructus Liquidambaris 15 gram Radix Notoginseng 10 gram Rhizoma Atractylodis Macrocephalaes 15 gram Herba Lobeliae Chinensis 18 gram Rhizoma Curcumae Longaes 20 gram Radix Rehmanniae Preparata 20 gram Radix Codonopsis 20 gram Semen Lablab Albums 15 gram Rhizoma Atractylodis 15 gram Rhizoma Alismatis 20 Herba Lycopi 15 Keshan medicines 10 grams
Above-mentioned each component mix homogeneously is ground into 150 order fine powders, is distributed into bag, every packed medicated powder 9 grams.One after each meal, is taken after mixing it with water with warm water at twice at two bags of every days.
Medicine of the present invention is Chinese medicine preparation, and is theoretical according to traditional Chinese medical science prescription, select medicine rationally, heat-clearing and toxic substances removing, inducing diuresis and reducing edema, benefiting QI and nourishing blood.Medicine of the present invention, through clinical observation patient for many years, evident in efficacy, the patient has remarkable result to allergic cutaneous vasculitis.
Clinical drug of the present invention is taken the result and is shown, following advantage is arranged:
It is raw material that the present invention selects natural plant, and each component meets the pharmaceutical control law regulation, utilizes the comprehensive function treatment allergic cutaneous vasculitis of the medicine of respectively distinguishing the flavor of, nontoxic to human body without chemicals, has no side effect, safe and reliable; The present invention is powder, and effective ingredient scatters and disappears few, and curative effect is high, and cheap, taking convenience is without any discomfort disease; Medicine of the present invention is obvious to patient's curative effect of allergic cutaneous vasculitis, and therapeutic effect is better than other medicines.
For showing that medicine of the present invention is to the therapeutic effect of allergic cutaneous vasculitis, the present invention does the clinical observation of system through the patient of 540 routine allergic cutaneous vasculitiss, and select medical history, the state of an illness, age and the allergic cutaneous vasculitis Patients with 300 Cases suitable with traditional therapy to organize as a comparison, age 19-74 year, course of disease 1-20; Test group: use medicine of the present invention; Matched group: use merely doctor trained in Western medicine conventional therapy (corticosteroid hormone, sulfone class medicine, nonsteroidal anti-inflammatory drug, antibiotic) scheme.Observation period is 3 months years, check after 3 months.Recovery from illness: subjective symptoms disappearance skin erythema tuberosity disappears, and blood sedimentation is normal; Produce effects: subjective symptoms disappears, and the skin erythema tuberosity obviously reduces, and blood sedimentation is normal; Effectively: subjective symptoms disappears substantially, and the skin erythema tuberosity is treated front minimizing, the blood sedimentation slight abnormality; Invalid.Subjective symptoms and inspection are all without progressive.Clinical comparison the results are shown in Table 1.
Table 1: take medicine of the present invention with the observation of curative effect of traditional Western medicine to allergic cutaneous vasculitis.
Two groups of effective percentage of table 1 relatively
Annotate: curative effect relatively adopts statistical method, and enumeration data adopts X
2Check, two groups of effective percentage compare P＜0.01
As can be seen from Table 1, two groups of effective percentage relatively: the experimental group total effective rate is 96.3%, and matched group is 40.6%, and experimental group obviously is better than matched group (P＜0.01), illustrates that medication effect of the present invention significantly is better than traditional Western medicine.
The specific embodiment:
Take by weighing raw material by following proportioning
Medicine of the present invention is made by following component:
The Flos Lonicerae 12 gram Radix Astragali Preparatas 16 gram Herba Artemisiae Scopariaes 12 gram Poria 18 gram Fructus Liquidambaris 15 gram Radix Notoginseng 10 gram Rhizoma Atractylodis Macrocephalaes 15 gram Herba Lobeliae Chinensis 18 gram Rhizoma Curcumae Longaes 20 gram Radix Rehmanniae Preparata 20 gram Radix Codonopsis 20 gram Semen Lablab Albums 15 gram Rhizoma Atractylodis 15 gram Rhizoma Alismatis 20 Herba Lycopi 15 Keshan medicines 10 grams
Above-mentioned each component mix homogeneously is ground into 150 order fine powders, is distributed into bag, every packed medicated powder 9 grams.One after each meal, is taken after mixing it with water with warm water at twice at two bags of every days.
Claims (1)
1. a medicine for the treatment of allergic cutaneous vasculitis is the powder of being made by the raw material of following weight proportioning: the Flos Lonicerae 12 gram Radix Astragali Preparatas 16 gram Herba Artemisiae Scopariaes 12 gram Poria 18 gram Fructus Liquidambaris 15 gram Radix Notoginseng 10 gram Rhizoma Atractylodis Macrocephalaes 15 gram Herba Lobeliae Chinensis 18 gram Rhizoma Curcumae Longaes 20 gram Radix Rehmanniae Preparata 20 gram Radix Codonopsis 20 gram Semen Lablab Albums 15 gram Rhizoma Atractylodis 15 gram Rhizoma Alismatis 20 Herba Lycopi 15 Keshan medicines 10 grams; Above-mentioned each component mix homogeneously is ground into 150 order fine powders, is distributed into bag, every packed medicated powder 9 grams.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110462360 CN102526613B (en) | 2011-12-30 | 2011-12-30 | Medicament for treating allergic cutaneous vasculitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110462360 CN102526613B (en) | 2011-12-30 | 2011-12-30 | Medicament for treating allergic cutaneous vasculitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102526613A CN102526613A (en) | 2012-07-04 |
| CN102526613B true CN102526613B (en) | 2013-05-29 |
Family
ID=46335433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110462360 Expired - Fee Related CN102526613B (en) | 2011-12-30 | 2011-12-30 | Medicament for treating allergic cutaneous vasculitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102526613B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105535570A (en) * | 2015-09-17 | 2016-05-04 | 刘波 | Traditional Chinese medicine for treating cutaneous allergic nodular vasculitis |
| CN105998687A (en) * | 2016-06-20 | 2016-10-12 | 刘艳 | Traditional Chinese medicine for treating allergic cutaneous vasculitis and preparation method |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101264070B (en) * | 2008-04-25 | 2010-06-02 | 梁勇才 | Dermatosis-treating medicine and preparation thereof |
-
2011
- 2011-12-30 CN CN 201110462360 patent/CN102526613B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN102526613A (en) | 2012-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102133271B (en) | Medicinal tea for curing gout | |
| CN101564486A (en) | Medicament for preventing and treating ruminant post-natal diseases and preparation method thereof | |
| CN103656122B (en) | Chinese medicine for the treatment of fever caused by exogenous pathogenic factors and preparation method thereof | |
| CN102526613B (en) | Medicament for treating allergic cutaneous vasculitis | |
| CN101239159B (en) | Chinese medicinal composition for treating rheumatoild disease and preparation thereof | |
| CN101194998B (en) | Chinese medicine for treating diabetes | |
| CN102552537B (en) | Chinese medicinal composition for treating qi and blood loss | |
| CN1246031C (en) | Chinese patent drug-Fuyan capsdule for treating chronic pelvic inflammation | |
| CN1097621A (en) | Anti-cancer powder | |
| CN101491612B (en) | Medicine for treating mammary hyperplasia and early breast cancer | |
| CN103007237B (en) | Medicine for treating idiopathic thrombocytopenic purpura (ITP) | |
| CN103405574B (en) | Medicinal composition for treating hypertension | |
| CN101850071A (en) | Chinese medicament for treating chronic nephritis | |
| CN104306847A (en) | Six-ingredient qi-tonifying capsule and preparation process thereof | |
| CN102512589B (en) | Medicine for treating early sudden deafness | |
| CN102552569B (en) | Medicine for treating renal artery type arteritis | |
| CN101554426B (en) | Traditional Chinese medicine for treating diabetic obstipation | |
| CN102512546B (en) | Traditional Chinese medicine used for esophageal cancer patients refusing surgery | |
| CN102406875A (en) | Drug for treating endometriosis interna | |
| CN102973803A (en) | Drug for treating hematopathy primary thrombocytopenic purpura | |
| CN102526364A (en) | Medicine for treating immune infertility | |
| CN103479956A (en) | Preparation method of traditional Chinese medicine with function of reinforcing spleen to promote digestion | |
| CN102526610A (en) | Traditional Chinese medicine for curing multiple takayasu arteritis | |
| CN102512637B (en) | Medicine for treating special chronic sinusitis of patients | |
| CN102908598B (en) | Medicine for treating children fungal pneumonia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130529 Termination date: 20131230 |